Observational studyEndocrinology, diabetes & metabolism2026
Long-Term Glycemic and Metabolic Profiles Observed During Imeglimin Therapy in Japanese Patients With Type 2 Diabetes Mellitus.
Observational study in Endocrinology, diabetes & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AIMS/
introductionImeglimin is a first-in-class oral antidiabetic agent that improves glycemia through dual actions on insulin secretion and sensitivity. However, real-world data on its long-term metabolic effects, particularly on endogenous insulin secretion, remain limited. We aimed to evaluate 12-month longitudinal changes in glycemic indices, an insulin secretion index, and treatment intensity during imeglimin therapy in routine clinical practice. MATERIALS AND
methodsThis retrospective observational study included 73 Japanese patients with type 2 diabetes mellitus who continued imeglimin therapy for approximately 12 months. Hemoglobin A1c (HbA1c) and glycated albumin (GA) were assessed at baseline and follow-up. Fasting plasma glucose and C-peptide levels obtained between 10 and 14 months after initiation were used to calculate the fasting C-peptide index (fCPI). Overall glucose-lowering treatment intensity was quantified using the medication effect score (MES).
resultsHbA1c significantly decreased from 8.55% ± 1.38% to 7.67% ± 0.99% over 12 months (p < 0.0001). GA also declined from the early phase after initiation, whereas the GA/HbA1c ratio showed only transient change without sustained differences. The fCPI increased from 1.14 [0.65-1.84] to 1.21 [0.79-2.01] (n = 69, p = 0.003), and an early increase was observed within 1-2 months. Despite frequent adjustments to background therapies, treatment intensity as assessed by MES did not change significantly.
conclusionsIn a real-world setting, long-term imeglimin therapy was associated with sustained glycemic improvement and early as well as sustained numerical changes in an insulin secretion index without an increase in overall treatment intensity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.